Adalimumab biosimilar - Momenta Pharmaceuticals

Drug Profile

Adalimumab biosimilar - Momenta Pharmaceuticals

Alternative Names: BAX 2923; M 923

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Shire
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis
  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 02 Aug 2017 Momenta Pharmaceuticals announces intention to file regulatory submission in the fourth quarter of 2017
  • 01 Apr 2017 Baxalta completes a phase III trial for Plaque psoriasis in USA, Bulgaria, Czech Republic, Germany, Poland, Canada, Estonia, Hungary, Latvia and Slovakia (SC) (NCT02581345)
  • 01 Feb 2017 Momenta Pharmaceuticals completes a phase-III trial in Rheumatoid arthritis in USA (SC) (NCT02722044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top